ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ORAMED PHARMACEUTICALS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$4.06−0.01 (-0.25%)
Close on Oct 19, 2026
- Market cap
- $172.56M
- P/E (TTM)
- 1.0
- Dividend yield
- 6.16%
Margins
Share of revenue, fiscal years 2010 to 2025
Gross margin
0.7%−96.0 pts over 5 years
Operating margin
-754.4%−213.1 pts over 5 years
Net margin
3202.5%+3733.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | – | -5.9% | – | |
| EPS, diluted | – | – | +21.8% | +8.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2015 | FY2019 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -31.7% | -56.8% | 37.0% | |
| Return on assets | -30.0% | -35.0% | 33.2% | |
| Current ratio | 11.67 | 6.28 | 6.98 | |
| Interest coverage | – | – | – | |
| Capex to revenue | – | 0.6% | 0.4% | |
| Diluted shares | 11M | 17M | 42M |
Where the cash went
Fiscal 2020 to 2025, five years combined
Oramed Pharmaceuticals generated $61.47M from operations and spent $7.96M on capital expenditure, dividends and share buybacks. 9% of that went back into the business.
Generated
$61.47M
Used
$7.96M
Capital expenditure$738.00K9%Dividends$00%Share buybacks$7.23M91%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin3202.5%
×Asset turnover0.01×
×Equity multiplier1.12×
=Return on equity, FY202537.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 3202.5% | 0.01× | 1.12× | 37.0% |
| FY2021 | -850.5% | 0.03× | 1.16× | -30.9% |
| FY2020 | -424.8% | 0.07× | 1.52× | -44.0% |
| FY2019 | -531.1% | 0.07× | 1.62× | -56.8% |
| FY2018 | -519.7% | 0.06× | 1.71× | -50.6% |
| FY2017 | -426.7% | 0.06× | 1.79× | -46.1% |
| FY2016 | -1710.5% | 0.02× | 1.36× | -43.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$64.05M
- Cash generatingOperating cash flow above zero-$9.15M
- Return on assets improvedROA up on the prior year-8.6% → 41.2%
- Earnings backed by cashOperating cash flow above net income-$9.15M vs $64.05M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose25.19 → 6.98
- No dilutionShare count did not rise41M → 42M
- Gross margin improvedGross margin up on the prior year– → 0.65%
- More efficientAsset turnover rose– → 0.01